SDHAF2

SDHAF2 (SDH5) is a mitochondrial assembly factor for succinate dehydrogenase (complex II) that physically interacts with the catalytic flavoprotein subunit SDHA and is required for its covalent flavinylation and SDH-dependent respiration (PMID:19628817). SDHAF2 does not itself bind FAD; instead, a conserved surface region forms the SDHA-binding interface, and mutations there abolish flavinylation, establishing SDHAF2 as a catalytic chaperone rather than a simple FAD transporter (PMID:23062074). In vitro reconstitution shows that flavinylation of recombinant apo-SDHA is fully dependent on SDHAF2 with an acidic pH optimum, acting at the covalent attachment step (PMID:27296776), and the human SDHA–SDHAF2 crystal structure resolves the mechanism: a small-molecule dicarboxylate cofactor works in synergy with SDHAF2 to reorient the SDHA flavin and capping domains and adjust the pKa of SDHA-R451 to enable covalent FAD attachment (PMID:32887801). SDHAF2 stability is coupled to this interaction—it is protected from LON protease degradation only when stably bound to SDHA, explaining the rapid turnover of the disease-associated G78R mutant, which fails to form a stable complex (PMID:24414418). This role is context-dependent: SDHAF2 is dispensable for SDHA flavination in certain breast cancer cells, which retain functional complex II via an alternative mechanism (PMID:27587393). Germline SDHAF2 mutation (G78R) causes hereditary paraganglioma, with the parent-of-origin tumor risk explained by maternal-allele loss of chromosome 11 in tumors (PMID:20071235, PMID:28099933). Beyond assembly, reported extramitochondrial functions include modulation of GSK-3β/β-catenin signaling driving EMT and metastasis (PMID:23983127) and regulation of p53 stability via the ubiquitin/proteasome pathway (PMID:31588224).

1. 2009 High

   Established the existence and core function of SDHAF2 by showing it is a dedicated interactor of the SDH catalytic subunit required for FAD attachment, defining a previously unrecognized assembly step for complex II.

   Evidence Yeast genetics, mitochondrial proteomics, and in vivo flavination/SDH activity assays in yeast and human systems

   PMID:19628817

   Open questions at the time

   • Did not resolve whether SDHAF2 acts catalytically or as an FAD carrier
   • No structural basis for the SDHA interface
   • Conservation of mechanism across cell types untested
2. 2012 High

   Defined SDHAF2 as a catalytic chaperone rather than an FAD transporter by mapping the SDHA-binding surface and demonstrating it does not bind FAD itself.

   Evidence Solution NMR structure of yeast Sdh5, chemical shift perturbation, site-directed mutagenesis, and in vivo flavinylation assays

   PMID:23062074

   Open questions at the time

   • Did not show how SDHAF2 promotes covalent attachment mechanistically
   • Human SDHAF2 structure not determined here
   • No co-structure with SDHA
3. 2010 Low

   Linked SDHAF2 to human disease by establishing the G78R mutation as pathogenic for hereditary paraganglioma, identifying Gly78 as a functionally critical residue.

   Evidence Germline mutation and haplotype analysis in two familial paraganglioma kindreds

   PMID:20071235

   Open questions at the time

   • No direct biochemical mechanism for G78R reported in this study
   • Parent-of-origin transmission unexplained at the molecular level
   • Tissue specificity of tumorigenesis unaddressed
4. 2014 High

   Explained why the G78R mutant is loss-of-function by showing SDHAF2 stability depends on SDHA binding, with unbound or mutant protein cleared by LON protease.

   Evidence Import-chase in isolated human mitochondria, in vitro LON degradation, BN-PAGE, and LONM/SDHA siRNA depletion

   PMID:24414418

   Open questions at the time

   • Structural reason for G78R destabilization not defined
   • Did not address whether LON regulates SDHAF2 levels physiologically
   • In vivo relevance to paraganglioma tissue untested
5. 2016 Medium

   Demonstrated by full in vitro reconstitution that SDHAF2 is strictly required for covalent flavinylation of apo-SDHA, acting at the attachment step under acidic conditions.

   Evidence In vitro flavinylation of recombinant immobilized apo-SDHA with purified SDH5 in defined medium

   PMID:27296776

   Open questions at the time

   • Single lab reconstitution
   • Did not identify the chemical role of accessory cofactors
   • Catalytic mechanism inferred, not visualized
6. 2016 Medium

   Revealed context dependence of SDHAF2 by showing it is dispensable for SDHA flavination in breast cancer cells, implying an alternative flavination route.

   Evidence CRISPR-Cas9 nickase knockout with complex II activity, respiration, and SDHA flavination assays

   PMID:27587393

   Open questions at the time

   • Identity of the alternative flavination mechanism unknown
   • Single cell-type/single lab observation
   • Reconciliation with strict in vitro dependence unresolved
7. 2020 High

   Resolved the molecular mechanism of SDHAF2-assisted flavinylation by capturing the human SDHA–SDHAF2 complex and identifying a dicarboxylate cofactor that, with SDHAF2, reorganizes the active site and tunes SDHA-R451 pKa.

   Evidence X-ray crystallography of the human SDHA–SDHAF2 complex with biochemical reconstitution and disease-mutant analysis

   PMID:32887801

   Open questions at the time

   • Dynamics of cofactor entry/exit not captured
   • Does not explain alternative flavination in some cancer cells
   • Extramitochondrial functions not addressed
8. 2017 Medium

   Provided the molecular basis for parent-of-origin tumor risk by showing maternal chromosome 11 loss in most SDHAF2-related paragangliomas, consistent with imprinting.

   Evidence FISH, microsatellite and SNP array analysis, and DMR methylation analysis of tumor specimens

   PMID:28099933

   Open questions at the time

   • Mechanism linking SDH loss to paraganglioma initiation not defined
   • Single study cohort
   • Does not establish the tumor-driving metabolic consequence
9. 2013 Medium

   Extended SDHAF2 function beyond assembly by linking its loss to EMT and metastasis through GSK-3β/β-catenin signaling in lung cancer.

   Evidence SDH5 knockdown/knockout in lung cancer cells and mice, EMT marker analysis, xenograft metastasis model, and pathway analysis

   PMID:23983127

   Open questions at the time

   • Mechanistic link between mitochondrial assembly role and GSK-3β signaling unclear
   • Direct molecular partners in the pathway not defined
   • Single lab
10. 2019 Medium

    Implicated SDHAF2 in p53 turnover, with depletion stabilizing p53 to promote apoptosis and radiosensitivity in NSCLC.

    Evidence SDH5 KO mice and xenografts, immunoprecipitation, GST pulldown, in vitro ubiquitination, and apoptosis/DNA-damage assays

    PMID:31588224

    Open questions at the time

    • Mechanism by which a mitochondrial assembly factor regulates p53 ubiquitination unresolved
    • Direct vs indirect interaction not fully separated
    • Single lab
11. 2019 Low

    Connected SDHAF2 loss to immune evasion by linking it to PD-L1 upregulation through GSK3β/β-catenin/ZEB1 signaling.

    Evidence SDH5 overexpression/knockdown in lung cancer cells, PD-L1 analysis in vitro and patient tissues, and pathway inhibitor experiments

    PMID:31741753

    Open questions at the time

    • Correlative pathway data with limited mechanistic depth
    • Not independently confirmed
    • Causal chain from SDHAF2 to ZEB1 not directly demonstrated
12. 2024 Medium

    Placed SDHAF2 within a mitochondrial morphology–metabolism axis by showing its mitochondrial import requires Drp1-mediated fission, with consequences for complex II activity and insulin sensitivity.

    Evidence Drp1 knockdown in mouse muscle, mitochondrial fractionation, complex II assays, Sdhaf2 rescue, and metabolic phenotyping

    PMID:38569044

    Open questions at the time

    • Mechanism coupling fission to SDHAF2 translocation undefined
    • Single lab
    • Generalizability beyond skeletal muscle untested

• How SDHAF2's canonical mitochondrial assembly role is mechanistically connected to its reported extramitochondrial functions (GSK-3β/β-catenin, p53, PD-L1) remains unresolved.
• No defined molecular bridge between complex II assembly and cytosolic signaling
• Alternative flavination mechanism unidentified
• Mechanism converting SDH loss into paraganglioma initiation undefined